弥漫大B细胞淋巴瘤的DNA甲基化改变及治疗进展

doi:10.11904/j.issn.1002-3070.2022.03.012

Abstract

Abstract: Diffuse large B-cell lymphoma(DLBCL)is a common type of adult lymphoma with high heterogeneity and different clinical and pathological features.Although some DLBCLs are curable,the management of refractory and relapsed patients remains challenging.In recent years,epigenetic modifications such as DNA methylation have become a research hotspot of DLBCL.Gene mutations regulating methylation modification and methylation modification of tumor suppressor genes play a key role in the pathogenesis and prognosis of DLBCL.This paper reviews the research progress of DNA methylation in DLBCL.

Key words: Diffuse large B-cell lymphoma, DNA methylation, Epigenetics, Targeted therapy

CLC Number:

R733.1

ZHENG Yanli, HE Jianxia. Research progress of DNA methylation in diffuse large B-cell lymphoma[J]. Journal of Practical Oncology, 2022, 36(3): 259-262.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.03.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I3/259

References

1 Hernández VI,Labreche K,Benazra M,et al.Tracking the genetic susceptibility background of B-cell non-hodgkin′s lymphomas from genome-wide association studies[J].Int J Mol Sci,2020,22(1):122.
2 李丽燕,付蓉.复发难治性弥漫大B细胞淋巴瘤靶向药物治疗进展[J].中国肿瘤临床,2019,46(11):581-585.
3 Licht JD,Bennett RL.Leveraging epigenetics to enhance the efficacy of immunotherapy[J].Clin Epigenetics,2021,13(1):115.
4 Wedge E,Hansen JW,Garde C,et al.Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma[J].Am J Hematol,2017,92(7):689-694.
5 Amara K,Ziadi S,Hachana M,et al.DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B-cell lymphomas[J].Cancer Sci,2010,101(7):1722-1730.
6 周怡,王鑫,安依涵,等.索拉非尼联合地西他滨协同作用诱导弥漫大B细胞淋巴瘤凋亡的机制研究[J].中国实验血液学杂志,2020,28(1):146-152.
7 马咪静.地西他滨治疗弥漫大B细胞淋巴瘤的临床疗效观察及生物学活性研究[D].郑州:郑州大学,2019.
8 Clozel T,Yang S,Elstrom RL,et al.Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma[J].Cancer Discov,2013,3(9):1002-1019.
9 Yin X,Xu Y.Structure and function of TET enzymes[J].Adv Exp Med Biol,2016,945:275-302.
10 Cimmino L,Dawlaty MM,Ndiaye-Lobry D,et al.TET1 is a tumor suppressor of hematopoietic malignancy[J].Nat Immunol,2015,16(6):653-662.
11 Quivoron C,Couronné L,Della Valle V,et al.TET2 Inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis[J].Cancer Cell,2011,20(1):25-38.
12 Vipul S,Daniela S,Zhen D,et al.TET deficiency perturbs mature B cell homeostasis and promotes oncogenesis associated with accumulation of G-quadruplex and R-loop structures[J].Nat Immunol 2022,23(1):99-108.
13 López-Moyado IF,Tsagaratou A,Yuita H,et al.Paradoxical association of TET loss of function with genome-wide DNA hypomethylation[J].Proc Natl Acad Sci U S A,2019,116(34):16933-16942.
14 Narayan G,Xie D,Freddy AJ,et al.PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis[J].Genes Chromosomes Cancer,2013,52(11):1030-1041.
15 Ying J,Gao Z,Li H,et al.Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies[J].Br J Haematol,2007,136(6):829-832.
16 Shi D,Murty VV,Gu W,et al.PCDH10,a novel p53 transcriptional target in regulating cell migration[J].Cell Cycle,2015,14(6):857-866.
17 Huang W,Xue X,Shan L,et al.Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma[J].BMC Cancer,2017,17(1):815.
18 薛伍君.弥漫大B细胞淋巴瘤PCDH10基因启动子甲基化状态及其临床意义[D].新乡:新乡医学院,2021.
19 Caiado F,Maia-Silva D,Jardim C,et al.Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection[J].Nat Commun,2019,10(1):4986.
20 Dan H,Zhang S,Zhou Y,et al.DNA methyltransferase inhibitors:catalysts for antitumour immune responses[J].Onco Targets Ther,2019,12:10903-10916.
21 Wright GW,Huang DW,Phelan JD,et al.A Probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications[J].Cancer Cell,2020,37(4):551-568.
22 Chen S,Wang Q,Yu H,et al.Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway[J].Nat Commun,2020,11(1):3856.

[1]	CHEN Su, SUI Hong. Research progress of anti-HER2 therapy in metastatic colorectal cancer [J]. Journal of Practical Oncology, 2022, 36(3): 288-292.
[2]	WU Fangfang, ZHENG Tongsen. Research status and prospect of adjuvant therapy for biliary tract malignant tumors [J]. Journal of Practical Oncology, 2022, 36(2): 156-161.
[3]	HOU Jianxun, WANG Hongbin. Research progress on the influence of exosomes in the integration of breast cancer diagnosis and treatment [J]. Journal of Practical Oncology, 2022, 36(2): 178-182.
[4]	MA Buhuan¹, LIU Caixia². Research progress of Jagged1 promoting the occurrence,development and distant metastasis of breast cancer [J]. Journal of Practical Oncology, 2021, 35(5): 452-457.
[5]	YANG Siqi,SONG Qibin,LI Qingqing,YAO Yi. Research progress of targeted inhibition of FGFRs signal in the treatment of malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 73-77.
[6]	SONG Jiayu, FENG Yue, WANG Zhao, ZHANG Yunyan. The latest research progress of the correlation between exosomes and gynecological malignant tumor [J]. Journal of Practical Oncology, 2020, 34(6): 571-575.
[7]	DENG Jun,YUAN Yuan,LUO Xuan,TAN Xiyan,YU Enhao,LIU Ke,WU Zheng,ZHOU Jumei,ZHU Suyu. The effect of early diffuse large B-cell lymphoma shrinking radiotherapy field on survival prognosis under chemoradiotherapy mode [J]. Journal of Practical Oncology, 2020, 34(3): 237-243.
[8]	FAN Xiaona,WANG Dan,LI Qingwei,LI Zhiwei. Advances in research on adjuvant drug threapy for postoperative pancreatic cancer [J]. Journal of Practical Oncology, 2020, 34(3): 249-253.
[9]	LI Guozheng, PANG Da. Progression in the treatment of HER2-positive breast cancer [J]. Journal of Practical Oncology, 2020, 34(1): 74-78.
[10]	ZUO Zhibo, GUO Zhiqin, WANG Zhen, YANG Hongjie, WU Wanxin. Research progress of Semaphorin 3F in tumors [J]. Journal of Practical Oncology, 2020, 34(1): 88-92.
[11]	ZHANG Yiwei, SHI Jing, LIU Yupeng, CAO Liming, HU Fulan, ZHAO Yashuang. Relationship between methylation of USP1 gene in peripheral blood and prognosis risk of colorectal cancer [J]. Journal of Practical Oncology, 2019, 33(5): 420-424.
[12]	HUANG Xianbo, SHI Ting, YE Xiujin. Progress in the treatment of acute T lymphoblastic leukemia by targeting PI3K/AKT/mTOR pathway [J]. Journal of Practical Oncology, 2019, 33(5): 451-455.
[13]	ZHANG Meiyin, LOU Ge. Advances progress of N6-methyladenine and cancer [J]. Journal of Practical Oncology, 2019, 33(4): 357-360.
[14]	ZHU Lin,ZHANG Chunxia. Research progress of the nano drug-loading systems targeting tumor stem cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 276-279.
[15]	HUANG Qianqian, MA Jianjia, WU Qiang, LIU Binbin, MU Xiaoqin, LIU Shulin. Research progress on tumor stem cells and tumor targeted therapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 533-537.

Research progress of DNA methylation in diffuse large B-cell lymphoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments